104 related articles for article (PubMed ID: 21692185)
1. Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists.
Pluym N; Brennauer A; Keller M; Ziemek R; Pop N; Bernhardt G; Buschauer A
ChemMedChem; 2011 Sep; 6(9):1727-38. PubMed ID: 21692185
[TBL] [Abstract][Full Text] [Related]
2. Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
Keller M; Pop N; Hutzler C; Beck-Sickinger AG; Bernhardt G; Buschauer A
J Med Chem; 2008 Dec; 51(24):8168-72. PubMed ID: 19053784
[TBL] [Abstract][Full Text] [Related]
3. N(G)-Acyl-argininamides as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity.
Weiss S; Keller M; Bernhardt G; Buschauer A; König B
Bioorg Med Chem; 2010 Sep; 18(17):6292-304. PubMed ID: 20688523
[TBL] [Abstract][Full Text] [Related]
4. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
[TBL] [Abstract][Full Text] [Related]
5. Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.
Weiss S; Keller M; Bernhardt G; Buschauer A; König B
Bioorg Med Chem; 2008 Nov; 16(22):9858-66. PubMed ID: 18851917
[TBL] [Abstract][Full Text] [Related]
6. Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
Keller M; Erdmann D; Pop N; Pluym N; Teng S; Bernhardt G; Buschauer A
Bioorg Med Chem; 2011 May; 19(9):2859-78. PubMed ID: 21493077
[TBL] [Abstract][Full Text] [Related]
7. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
Keller M; Teng S; Bernhardt G; Buschauer A
ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
[TBL] [Abstract][Full Text] [Related]
9. Toward Labeled Argininamide-Type NPY Y1 Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304.
Keller M; Schindler L; Bernhardt G; Buschauer A
Arch Pharm (Weinheim); 2015 Jun; 348(6):390-8. PubMed ID: 25884646
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
[TBL] [Abstract][Full Text] [Related]
11. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
[TBL] [Abstract][Full Text] [Related]
13. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
14. A simple and powerful flow cytometric method for the simultaneous determination of multiple parameters at G protein-coupled receptor subtypes.
Schneider E; Mayer M; Ziemek R; Li L; Hutzler C; Bernhardt G; Buschauer A
Chembiochem; 2006 Sep; 7(9):1400-9. PubMed ID: 16888730
[TBL] [Abstract][Full Text] [Related]
15. [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
Pluym N; Baumeister P; Keller M; Bernhardt G; Buschauer A
ChemMedChem; 2013 Apr; 8(4):587-93. PubMed ID: 23361914
[TBL] [Abstract][Full Text] [Related]
16. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
Murakami Y; Hara H; Okada T; Hashizume H; Kii M; Ishihara Y; Ishikawa M; Shimamura M; Mihara S; Kato G; Hanasaki K; Hagishita S; Fujimoto M
J Med Chem; 1999 Jul; 42(14):2621-32. PubMed ID: 10411482
[TBL] [Abstract][Full Text] [Related]
17. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
[TBL] [Abstract][Full Text] [Related]
18. Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
Keller M; Kuhn KK; Einsiedel J; Hübner H; Biselli S; Mollereau C; Wifling D; Svobodová J; Bernhardt G; Cabrele C; Vanderheyden PM; Gmeiner P; Buschauer A
J Med Chem; 2016 Mar; 59(5):1925-45. PubMed ID: 26824643
[TBL] [Abstract][Full Text] [Related]
19. [3H]-BIBP3226 and [3H]-NPY binding to intact SK-N-MC cells and CHO cells expressing the human Y1 receptor.
Vanderheyden PM; Van Liefde I; de Backer JP; Vauquelin G
J Recept Signal Transduct Res; 1998; 18(4-6):363-85. PubMed ID: 9879066
[TBL] [Abstract][Full Text] [Related]
20. Preparation of fluorescent nonpeptidic neuropeptide Y receptor ligands: analogues of the quinazoline-type anti-obesity Y5 antagonist CGP 71683A.
Li L; Mayer M; Schneider E; Schreiber E; Bernhardt G; Peng S; Buschauer A
Arch Pharm (Weinheim); 2003 Dec; 336(12):585-90. PubMed ID: 14677152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
